Claudia Dominici

Foghorn Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

3h-index99citations21works0.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related gene regulation(12), CAR-T cell therapy research(9), Virus-based gene therapy research(4), Muscle Physiology and Disorders(3), Metal complexes synthesis and properties(2)

Publications21 total

Abstract 7186: Anti-cancer activity of potent and selective EP300 degradation in hematological malignancies
Cancer Research·2025
Abstract 1643: Establishing rational combination strategies with selective CBP degraders in solid tumor indications
Cancer Research·2025
Abstract 6067: Identification of selective CBP degraders with robust preclinical PK, PD, efficacy and safety across solid tumor indications
Cancer Research·2024· 1 cited
Abstract 6064: Discovery of potent and selective EP300 degraders with anti-cancer activity
Cancer Research·2024· 2 cited
Abstract 7185: Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models
Cancer Research·2024
Abstract A049: Investigation of FHD-609, a potent degrader of BRD9, in preclinical models of acute myeloid leukemia (AML)
Molecular Cancer Therapeutics·2023· 5 cited
Abstract A058: Investigating the molecular role of BRD9 in synovial sarcoma
Molecular Cancer Therapeutics·2023
Inhibition of type I PRMTs reforms muscle stem cell identity enhancing their therapeutic capacity
eLife·2023Open Access
Author Response: Inhibition of type I PRMTs reforms muscle stem cell identity enhancing their therapeutic capacity
2023Open Access
Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Author Response: Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Reviewer #1 (Public Review): Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Reviewer #3 (Public Review): Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Inhibition of type I PRMTs reforms muscle stem cell identity enhancing their therapeutic capacity
eLife·2023· 3 citedOpen Access
Reviewer #2 (Public Review): Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Author Response: Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Inhibition of Type I PRMTs Reforms Muscle Stem Cell Identity Enhancing their Therapeutic Capacity
2023Open Access
Muscle stem cell polarity requires QKI-mediated alternative splicing of Integrin Alpha-7 (Itga7)
Life Science Alliance·2022· 12 citedOpen Access
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
Clinical Epigenetics·2021· 74 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Stéphane Richard(13), Junio Dort(11), Émilie Heckel(11), Ioannis Ragoussis(11), Jean‐Sébastien Joyal(11), Nicolas A. Dumont(11), Yu Chang Wang(8), Qianhe Zhou(7), Mei Yun Lin(6), Oscar D. Villarreal(6), David L. Mayhew(5), Ammar Adam(5), Hafiz Ahmad(5), Oscar Villareal(5), Mark W. Zimmerman(4), Wesley Austin(4), Brian Ethell(4), Laura La Bonte(4), Brandon Antonakos(3), Scott Innis(3)